360 related articles for article (PubMed ID: 32493529)
1. Biophysical studies of protein misfolding and aggregation in
Sinnige T; Stroobants K; Dobson CM; Vendruscolo M
Q Rev Biophys; 2020 Jun; 49():e22. PubMed ID: 32493529
[TBL] [Abstract][Full Text] [Related]
2. Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases.
Choi ML; Gandhi S
FEBS J; 2018 Oct; 285(19):3631-3644. PubMed ID: 29924502
[TBL] [Abstract][Full Text] [Related]
3. How an Infection of Sheep Revealed Prion Mechanisms in Alzheimer's Disease and Other Neurodegenerative Disorders.
Carlson GA; Prusiner SB
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34064393
[TBL] [Abstract][Full Text] [Related]
4. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
Coskuner-Weber O; Uversky VN
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151
[TBL] [Abstract][Full Text] [Related]
5. Shedding light on aberrant interactions - a review of modern tools for studying protein aggregates.
Kundel F; Tosatto L; Whiten DR; Wirthensohn DC; Horrocks MH; Klenerman D
FEBS J; 2018 Oct; 285(19):3604-3630. PubMed ID: 29453901
[TBL] [Abstract][Full Text] [Related]
6. Protein folding, misfolding and aggregation: The importance of two-electron stabilizing interactions.
Cieplak AS
PLoS One; 2017; 12(9):e0180905. PubMed ID: 28922400
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Amyloid Switch Triggered by Early Heterotypic Oligomerization of Intrinsically Disordered α-Synuclein and Tau.
Bhasne K; Sebastian S; Jain N; Mukhopadhyay S
J Mol Biol; 2018 Aug; 430(16):2508-2520. PubMed ID: 29704492
[TBL] [Abstract][Full Text] [Related]
8. A Fragment-Based Method of Creating Small-Molecule Libraries to Target the Aggregation of Intrinsically Disordered Proteins.
Joshi P; Chia S; Habchi J; Knowles TP; Dobson CM; Vendruscolo M
ACS Comb Sci; 2016 Mar; 18(3):144-53. PubMed ID: 26923286
[TBL] [Abstract][Full Text] [Related]
9. Focus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimer's and Parkinson's Disease.
Vella LJ; Hill AF; Cheng L
Int J Mol Sci; 2016 Feb; 17(2):173. PubMed ID: 26861304
[TBL] [Abstract][Full Text] [Related]
10. Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.
Nguyen PH; Ramamoorthy A; Sahoo BR; Zheng J; Faller P; Straub JE; Dominguez L; Shea JE; Dokholyan NV; De Simone A; Ma B; Nussinov R; Najafi S; Ngo ST; Loquet A; Chiricotto M; Ganguly P; McCarty J; Li MS; Hall C; Wang Y; Miller Y; Melchionna S; Habenstein B; Timr S; Chen J; Hnath B; Strodel B; Kayed R; Lesné S; Wei G; Sterpone F; Doig AJ; Derreumaux P
Chem Rev; 2021 Feb; 121(4):2545-2647. PubMed ID: 33543942
[TBL] [Abstract][Full Text] [Related]
11. Is there a risk of prion-like disease transmission by Alzheimer- or Parkinson-associated protein particles?
Beekes M; Thomzig A; Schulz-Schaeffer WJ; Burger R
Acta Neuropathol; 2014 Oct; 128(4):463-76. PubMed ID: 25073522
[TBL] [Abstract][Full Text] [Related]
12. Neuropathological and Biomarker Findings in Parkinson's Disease and Alzheimer's Disease: From Protein Aggregates to Synaptic Dysfunction.
Compta Y; Revesz T
J Parkinsons Dis; 2021; 11(1):107-121. PubMed ID: 33325398
[TBL] [Abstract][Full Text] [Related]
13. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
Hashimoto M; Rockenstein E; Crews L; Masliah E
Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
[TBL] [Abstract][Full Text] [Related]
14. The role of heparan sulfates in protein aggregation and their potential impact on neurodegeneration.
Maïza A; Chantepie S; Vera C; Fifre A; Huynh MB; Stettler O; Ouidja MO; Papy-Garcia D
FEBS Lett; 2018 Dec; 592(23):3806-3818. PubMed ID: 29729013
[TBL] [Abstract][Full Text] [Related]
15. One or more β-amyloid(s)? New insights into the prion-like nature of Alzheimer's disease.
Catania M; Di Fede G
Prog Mol Biol Transl Sci; 2020; 175():213-237. PubMed ID: 32958234
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.
Tsigelny IF; Crews L; Desplats P; Shaked GM; Sharikov Y; Mizuno H; Spencer B; Rockenstein E; Trejo M; Platoshyn O; Yuan JX; Masliah E
PLoS One; 2008 Sep; 3(9):e3135. PubMed ID: 18769546
[TBL] [Abstract][Full Text] [Related]
17. From Kuru to Alzheimer: A personal outlook.
Brunori M
Protein Sci; 2021 Sep; 30(9):1776-1792. PubMed ID: 34118168
[TBL] [Abstract][Full Text] [Related]
18. Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases.
Braak H; Del Tredici K
Cold Spring Harb Perspect Biol; 2016 Nov; 8(11):. PubMed ID: 27580631
[TBL] [Abstract][Full Text] [Related]
19. Aβ, Tau, and α-Synuclein aggregation and integrated role of PARK2 in the regulation and clearance of toxic peptides.
Kumar D; Kumar P
Neuropeptides; 2019 Dec; 78():101971. PubMed ID: 31540705
[TBL] [Abstract][Full Text] [Related]
20. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.
Hannula MJ; Myöhänen TT; Tenorio-Laranga J; Männistö PT; Garcia-Horsman JA
Neuroscience; 2013 Jul; 242():140-50. PubMed ID: 23562579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
